300122 智飞生物
已收盘 12-24 15:00:00
资讯
新帖
简况
智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗临床试验申请获得受理
智通财经 · 12-17
智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗临床试验申请获得受理
12月11日智飞生物创60日新低，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 12-11
12月11日智飞生物创60日新低，招商国证生物医药指数(LOF)C基金重仓该股
12月4日智飞生物现1笔大宗交易 机构净买入399.2万元
证券之星 · 12-04
12月4日智飞生物现1笔大宗交易 机构净买入399.2万元
智飞生物：截至2025年11月20日股东人数为130,074
证券之星 · 11-28
智飞生物：截至2025年11月20日股东人数为130,074
智飞生物（300122）披露重组带状疱疹ZFA01佐剂疫苗临床试验申请获受理，11月20日股价上涨0.48%
证券之星 · 11-20
智飞生物（300122）披露重组带状疱疹ZFA01佐剂疫苗临床试验申请获受理，11月20日股价上涨0.48%
智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)临床试验申请获受理
智通财经网 · 11-19
智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)临床试验申请获受理
智飞生物（300122）披露2025年第二次临时股东会决议公告，11月19日股价下跌0.95%
证券之星 · 11-19
智飞生物（300122）披露2025年第二次临时股东会决议公告，11月19日股价下跌0.95%
股市必读：智飞生物(300122)股东户数13.31万户，较上期增加1.19%
证券之星 · 11-17
股市必读：智飞生物(300122)股东户数13.31万户，较上期增加1.19%
智飞生物：四价流感疫苗已获批上市
证券之星 · 11-14
智飞生物：四价流感疫苗已获批上市
智飞生物：截至2025年11月10日股东人数为133,119
证券之星 · 11-14
智飞生物：截至2025年11月10日股东人数为133,119
智飞生物（300122）发布带状疱疹mRNA疫苗临床试验申请获得受理的公告，11月12日股价下跌0.69%
证券之星 · 11-12
智飞生物（300122）发布带状疱疹mRNA疫苗临床试验申请获得受理的公告，11月12日股价下跌0.69%
智飞生物(300122.SZ)：冻干水痘灭活疫苗临床试验申请获得受理
智通财经网 · 11-12
智飞生物(300122.SZ)：冻干水痘灭活疫苗临床试验申请获得受理
智飞生物(300122.SZ)：吸附无细胞百白破(组分)联合疫苗(成人及青少年用)获得临床试验批准通知书
智通财经 · 11-11
智飞生物(300122.SZ)：吸附无细胞百白破(组分)联合疫苗(成人及青少年用)获得临床试验批准通知书
智飞生物(300122)9月30日股东户数13.16万户，较上期减少3.17%
证券之星 · 10-30
智飞生物(300122)9月30日股东户数13.16万户，较上期减少3.17%
智飞生物：选举杨世龙为职工代表董事
证券日报 · 10-29
智飞生物：选举杨世龙为职工代表董事
智飞生物最新公告：前三季度净利润亏损12.06亿元
证券之星 · 10-29
智飞生物最新公告：前三季度净利润亏损12.06亿元
股市必读：智飞生物（300122）10月17日董秘有最新回复
证券之星 · 10-20
股市必读：智飞生物（300122）10月17日董秘有最新回复
智飞生物：与GSK独家探索RSV疫苗商业化合作
证券之星 · 10-17
智飞生物：与GSK独家探索RSV疫苗商业化合作
一针难求？RSV来袭预防需求激增 企业加速抢占婴幼儿市场
滚动播报 · 10-12
一针难求？RSV来袭预防需求激增 企业加速抢占婴幼儿市场
智飞生物最新公告：公司自主产品流感病毒裂解疫苗获得药品注册证书
证券之星 · 09-29
智飞生物最新公告：公司自主产品流感病毒裂解疫苗获得药品注册证书
加载更多
公司概况
公司名称：
重庆智飞生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2010-09-28
主营业务：
重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是预防流脑疫苗、宫颈癌疫苗、肺炎疫苗、流感疫苗、轮状病疫苗。
发行价格：
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":19.15,"timestamp":1766559792000,"preClose":19.04,"halted":0,"volume":8683757,"delay":0,"changeRate":0.0058,"floatShares":1414000000,"shares":2394000000,"eps":-0.5592,"marketStatus":"已收盘","change":0.11,"latestTime":"12-24 15:00:00","open":19.05,"high":19.2,"low":18.98,"amount":166000000,"amplitude":0.0116,"askPrice":19.16,"askSize":427,"bidPrice":19.15,"bidSize":154,"shortable":0,"etf":0,"ttmEps":-0.5592,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766626200000},"marketStatusCode":5,"adr":0,"adjPreClose":19.04,"symbolType":"stock","openAndCloseTimeList":[[1766539800000,1766547000000],[1766552400000,1766559600000]],"highLimit":20.94,"lowLimit":17.14,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":1.55,"roa":"--","roe":"--","epsLYR":0.8427,"committee":-0.509037,"marketValue":45841000000,"turnoverRate":0.0061,"status":0,"floatMarketCap":27084000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2592600029","title":"智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592600029","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592600029?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:39","pubTimestamp":1765960757,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由全资子公司安徽智飞龙科马生物制药有限公司研发的改良型安卡拉痘苗病毒猴痘减毒活疫苗获得国家药品监督管理局药物临床试验申请受理通知书。公司的改良型安卡拉痘苗病毒猴痘减毒活疫苗采用减毒活疫苗技术路线，利用改良型安卡拉痘苗病毒Ankara株进行疫苗生产，Ankara株无法在人体细胞中有效复制，不会在身体中扩散或造成继发传播，安全性较高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗临床试验申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892862.HKD","BK0046","LU1064131003.USD","LU2148510915.USD","LU2580892789.USD","BK0196","BK0239","LU1064130708.USD","BK0077","BK0188","LU1328615791.USD","300122"],"gpt_icon":0},{"id":"2590600445","title":"12月11日智飞生物创60日新低，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590600445","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590600445?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:37","pubTimestamp":1765438643,"startTime":"0","endTime":"0","summary":"证券之星消息，12月11日智飞生物创60日新低，收盘报19.38元，当日跌2.22%，换手率0.99%，成交量13.98万手，成交额2.73亿元。重仓智飞生物的前十大公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共15家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.4034，较上一交易日上涨0.52%，近一年下跌0.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100019607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0046","LU2580892789.USD","BK0188","LU1064131003.USD","BK0077","300122","399441","LU1064130708.USD","LU2580892862.HKD","BK0239","LU1328615791.USD","161726","BK0196"],"gpt_icon":0},{"id":"2588200248","title":"12月4日智飞生物现1笔大宗交易 机构净买入399.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588200248","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588200248?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:58","pubTimestamp":1764838701,"startTime":"0","endTime":"0","summary":"证券之星消息，12月4日智飞生物发生大宗交易，交易数据如下：大宗交易成交价格19.96元，成交20万股，成交金额399.2万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易，合计成交2000.0手。该股近期无解禁股上市。截至2025年12月4日收盘，智飞生物(300122)报收于19.96元，下跌0.25%，换手率0.81%，成交量11.52万手，成交额2.29亿元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400025509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","LU2580892862.HKD","BK0239","BK0188","LU1328615791.USD","LU2580892789.USD","LU1064131003.USD","LU1064130708.USD","300122","BK0196","BK0046","LU2148510915.USD"],"gpt_icon":0},{"id":"2586207619","title":"智飞生物：截至2025年11月20日股东人数为130,074","url":"https://stock-news.laohu8.com/highlight/detail?id=2586207619","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586207619?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:57","pubTimestamp":1764320229,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)11月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截至11月20日的股东人数是多少，谢谢智飞生物回复：您好，截至2025年11月20日，公司普通股股东人数为130,074，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800023938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0196","LU2148510915.USD","BK0046","LU1328615791.USD","BK0188","BK0077","LU1064130708.USD","LU1064131003.USD","BK0239","LU2580892862.HKD","LU2580892789.USD"],"gpt_icon":0},{"id":"2584200182","title":"智飞生物（300122）披露重组带状疱疹ZFA01佐剂疫苗临床试验申请获受理，11月20日股价上涨0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584200182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584200182?lang=zh_cn&edition=full","pubTime":"2025-11-20 17:43","pubTimestamp":1763631801,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘，智飞生物报收于20.94元，较前一交易日上涨0.48%，最新总市值为501.26亿元。该股当日开盘21.36元，最高21.77元，最低20.92元，成交额达6.67亿元，换手率为2.21%。近日，智飞生物发布公告称，公司全资子公司安徽智飞龙科马生物制药有限公司研发的重组带状疱疹ZFA01佐剂疫苗临床试验申请已获国家药品监督管理局受理，受理号为CXSL2500978。目前该事项对公司近期业绩无重大影响，后续临床试验进度及上市存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000026531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","300122","BK0077","LU1328615791.USD","LU2148510915.USD","BK0046","BK0188","159646","BK0239","BK0196","LU1064130708.USD","LU2580892862.HKD","LU1064131003.USD"],"gpt_icon":0},{"id":"2584494914","title":"智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2584494914","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584494914?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:37","pubTimestamp":1763545060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，公司全资子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)研发的重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得国家药品监督管理局药物临床试验申请受理通知书。自受理之日起60日内，未收到药审中心否定或质疑意见的，智飞龙科马可以按照提交的方案开展临床试验。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)临床试验申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1064130708.USD","159646","LU1328615791.USD","BK0188","BK0046","BK0239","LU1064131003.USD","LU2580892789.USD","300122","BK0196","LU2580892862.HKD","BK0077","LU2148510915.USD"],"gpt_icon":0},{"id":"2584914686","title":"智飞生物（300122）披露2025年第二次临时股东会决议公告，11月19日股价下跌0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584914686","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584914686?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:27","pubTimestamp":1763544451,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘，智飞生物报收于20.84元，较前一交易日下跌0.95%，最新总市值为498.87亿元。该股当日开盘21.05元，最高21.16元，最低20.73元，成交额达3.05亿元，换手率为1.03%。近日，重庆智飞生物制品股份有限公司发布2025年第二次临时股东会决议公告。本次会议采取现场与网络投票相结合的方式进行，出席股东共计743人，代表股份占公司有表决权股份总数的56.4371%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900027740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","LU1064130708.USD","LU2580892862.HKD","LU1064131003.USD","BK0196","BK0077","LU2580892789.USD","LU2148510915.USD","BK0239","LU1328615791.USD","BK0046","BK0188"],"gpt_icon":0},{"id":"2584660724","title":"股市必读：智飞生物(300122)股东户数13.31万户，较上期增加1.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584660724","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584660724?lang=zh_cn&edition=full","pubTime":"2025-11-17 01:20","pubTimestamp":1763313624,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，智飞生物报收于21.52元，下跌0.78%，换手率1.91%，成交量27.02万手，成交额5.88亿元。来自股本股东变化：截至11月10日股东户数增至13.31万户，户均持股数量下降至1.8万股，表明筹码略有分散。股本股东变化股东户数变动近日智飞生物披露，截至2025年11月10日公司股东户数为13.31万户，较9月30日增加1562.0户，增幅为1.19%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700000493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0196","BK0077","LU1064131003.USD","LU2148510915.USD","BK0188","LU2580892862.HKD","LU2580892789.USD","BK0046","BK0239","LU1064130708.USD","300122"],"gpt_icon":0},{"id":"2583573326","title":"智飞生物：四价流感疫苗已获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2583573326","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583573326?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:18","pubTimestamp":1763108291,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物11月14日在投资者关系平台上答复投资者关心的问题。23年4月董秘在互动易回复是四价流感疫苗已完成临床试验，时隔两年多了，目前这款疫苗上市了吗？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400024995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2580892789.USD","BK0196","LU1064131003.USD","BK0188","LU2148510915.USD","LU2580892862.HKD","BK0046","300122","LU1328615791.USD","BK0077","BK0239"],"gpt_icon":0},{"id":"2583357358","title":"智飞生物：截至2025年11月10日股东人数为133,119","url":"https://stock-news.laohu8.com/highlight/detail?id=2583357358","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583357358?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:15","pubTimestamp":1763108118,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)11月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问11月10日的股东人数多少，谢谢智飞生物回复：您好，截至2025年11月10日，公司普通股股东人数为133,119，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400024670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300122","LU1328615791.USD","BK0188","LU1064131003.USD","LU2148510915.USD","BK0196","LU2580892862.HKD","BK0239","LU1064130708.USD","LU2580892789.USD","BK0077"],"gpt_icon":0},{"id":"2582377876","title":"智飞生物（300122）发布带状疱疹mRNA疫苗临床试验申请获得受理的公告，11月12日股价下跌0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582377876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582377876?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:17","pubTimestamp":1762957038,"startTime":"0","endTime":"0","summary":"近日，重庆智飞生物制品股份有限公司全资子公司安徽智飞龙科马生物制药有限公司研发的带状疱疹mRNA疫苗临床试验申请已获国家药品监督管理局受理，受理号为CXSL2500961。该疫苗用于预防带状疱疹病毒感染，是国内尚无上市的mRNA疫苗类型。公司通过重组蛋白技术和mRNA等多条技术路径布局带状疱疹疫苗研发，本次申请受理标志着公司在mRNA技术平台应用方面取得进展，有助于丰富成人疫苗产品线，完善产品布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","LU2580892862.HKD","BK0239","BK0188","LU1328615791.USD","LU2580892789.USD","LU1064131003.USD","LU1064130708.USD","300122","159646","BK0196","BK0046","LU2148510915.USD"],"gpt_icon":0},{"id":"2582032136","title":"智飞生物(300122.SZ)：冻干水痘灭活疫苗临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2582032136","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582032136?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:26","pubTimestamp":1762939560,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由全资子公司安徽智飞龙科马生物制药有限公司研发的冻干水痘灭活疫苗获得国家药品监督管理局药物临床试验申请受理通知书。自受理之日起60日内，未收到药审中心否定或质疑意见的，智飞龙科马可以按照提交的方案开展临床试验。智飞龙科马研发的冻干水痘灭活疫苗采用创新灭活技术路线，生产用细胞株、毒株均为公司自主研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2148510915.USD","LU1064131003.USD","LU2580892862.HKD","BK0046","BK0196","300122","LU1064130708.USD","LU1328615791.USD","BK0077","BK0188","BK0239","LU2580892789.USD"],"gpt_icon":0},{"id":"2582359081","title":"智飞生物(300122.SZ)：吸附无细胞百白破(组分)联合疫苗(成人及青少年用)获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582359081","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582359081?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:52","pubTimestamp":1762851128,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)发布公告，公司于近日获悉，由全资子公司北京智飞绿竹生物制药有限公司(简称“智飞绿竹”)研发的吸附无细胞百白破(组分)联合疫苗(成人及青少年用)(简称“青少年及成人组分百白破疫苗”)获得国家药品监督管理局药物临床试验批准通知书(通知书编号：2025LP02971)，同意开展预防白喉、破伤风、百日咳引起的感染性疾病的临床试验。公司将根据临床试验批准通知书的要求，尽快开展相关临床试验工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：吸附无细胞百白破(组分)联合疫苗(成人及青少年用)获得临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","LU2580892862.HKD","BK0239","BK0188","LU1328615791.USD","LU2580892789.USD","LU1064131003.USD","LU1064130708.USD","300122","BK0196","BK0046","LU2148510915.USD"],"gpt_icon":0},{"id":"2579135201","title":"智飞生物(300122)9月30日股东户数13.16万户，较上期减少3.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579135201","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579135201?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:43","pubTimestamp":1761817428,"startTime":"0","endTime":"0","summary":"证券之星消息，近日智飞生物披露，截至2025年9月30日公司股东户数为13.16万户，较9月19日减少4311.0户，减幅为3.17%。在生物制品行业个股中，智飞生物股东户数高于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.41万户。根据统计，智飞生物2025年9月19日至2025年9月30日，主力资金净流出3.0亿元，游资资金净流入6323.92万元，散户资金净流入2.37亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000034176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","300122","BK0196","BK0046","LU2148510915.USD","LU2580892789.USD","LU1328615791.USD","BK0239","LU1064130708.USD","LU2580892862.HKD","LU1064131003.USD"],"gpt_icon":0},{"id":"2579826907","title":"智飞生物：选举杨世龙为职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2579826907","media":"证券日报 ","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579826907?lang=zh_cn&edition=full","pubTime":"2025-10-29 21:50","pubTimestamp":1761745800,"startTime":"0","endTime":"0","summary":"证券日报网讯 10月29日晚间，智飞生物发布公告称，公司于2025年10月28日召开了职工代表大会，经过民主讨论、表决，选举杨世龙先生为公司第六届职工代表董事。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-29/doc-infvqrtz3091090.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-29/doc-infvqrtz3091090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2148510915.USD","BK0188","BK0046","LU1064130708.USD","LU2580892789.USD","LU1328615791.USD","BK0077","LU1064131003.USD","300122","BK0239","BK0196","LU2580892862.HKD"],"gpt_icon":0},{"id":"2579385906","title":"智飞生物最新公告：前三季度净利润亏损12.06亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579385906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579385906?lang=zh_cn&edition=full","pubTime":"2025-10-29 20:41","pubTimestamp":1761741670,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司发布2025年第三季度报告，前三季度实现营业收入76.27亿元，同比下降66.53%；归属于上市公司股东的净利润为亏损12.06亿元。第三季度营业收入为27.05亿元，同比下降40.26%；归属于上市公司股东的净利润为亏损6.01亿元。业绩下滑主要系本期市场销售未达预期，收入减少所致，同时计提存货跌价准备增加及银行借款利息支出上升进一步影响利润表现。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900041841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122"],"gpt_icon":0},{"id":"2576314077","title":"股市必读：智飞生物（300122）10月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2576314077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576314077?lang=zh_cn&edition=full","pubTime":"2025-10-20 01:03","pubTimestamp":1760893388,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，智飞生物报收于20.05元，下跌2.53%，换手率1.61%，成交量22.78万手，成交额4.63亿元。董秘最新回复投资者： 贵司跟GSK签订的RSV疫苗独家代理推广，目前进展到什么程度？董秘： 您好，根据公司与GSK于2024年12月签署的补充协议约定，公司与GSK在中国大陆地区独家探索并积极促成初步为期10年的RSV疫苗商业化合作。当日关注点来自“交易信息汇总”：10月17日主力资金净流出5250.27万元，显示主力短期内呈离场态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000000466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0196","LU2148510915.USD","BK0046","LU1328615791.USD","BK0188","BK0077","LU1064130708.USD","LU1064131003.USD","BK0239","LU2580892862.HKD","LU2580892789.USD"],"gpt_icon":0},{"id":"2576381990","title":"智飞生物：与GSK独家探索RSV疫苗商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2576381990","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576381990?lang=zh_cn&edition=full","pubTime":"2025-10-17 17:30","pubTimestamp":1760693447,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)10月17日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司跟GSK签订的RSV疫苗独家代理推广，目前进展到什么程度？预计什么时候开始贡献收入？智飞生物回复：您好，根据公司与GSK于2024年12月签署的补充协议约定，公司与GSK在中国大陆地区独家探索并积极促成初步为期10年的RSV疫苗商业化合作。具体情况以双方后续商议并另行签署的协议为准。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700027812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1064130708.USD","BK0046","BK0196","LU1328615791.USD","159646","LU1064131003.USD","BK0077","300122","LU2148510915.USD","LU2580892862.HKD","LU2580892789.USD","BK0188"],"gpt_icon":0},{"id":"2574461129","title":"一针难求？RSV来袭预防需求激增 企业加速抢占婴幼儿市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2574461129","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574461129?lang=zh_cn&edition=full","pubTime":"2025-10-12 00:25","pubTimestamp":1760199900,"startTime":"0","endTime":"0","summary":"据中国疾控中心10月9日发布的今年第40周全国急性呼吸道传染病哨点监测数据显示，RSV在哨点医院门急诊流感样病例、住院严重急性呼吸道感染病例的呼吸道样本检测阳性率中，均位列第二。 在RSV持续高发的背景下，其预防与治疗的市场想象空间不断被放大，一场聚焦该赛道的药物研发竞速赛正拉开帷幕，尽显百舸争流之态。 截至目前，全球尚无专门靶向RSV的特效药获批，现有干预以对症治疗为主。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-12/doc-inftpzyh5284825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02257","159982","BK0070","300122","06660","BK0239","LU1064131003.USD","BK0077","01672","LU1328615791.USD","LU2580892789.USD","300142","LU2580892862.HKD","BK1515","BK0196","BK1161","LU1064130708.USD","LU2148510915.USD","688443","BK0188","BK1574","BK0046","688276"],"gpt_icon":0},{"id":"2571771380","title":"智飞生物最新公告：公司自主产品流感病毒裂解疫苗获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2571771380","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571771380?lang=zh_cn&edition=full","pubTime":"2025-09-29 19:39","pubTimestamp":1759145970,"startTime":"0","endTime":"0","summary":"智飞生物公告称，公司全资子公司智飞龙科马研发的流感病毒裂解疫苗获得国家药品监督管理局出具的《药品注册证书》。此次获得药品注册证书的三价流感疫苗，与公司已获批上市的四价流感病毒裂解疫苗、处于申报上市审评中的四价/三价流感病毒裂解疫苗（儿童型）、处于I/Ⅱ期临床试验的四价流感病毒裂解疫苗及已获批临床的三价流感病毒裂解疫苗构成覆盖全年龄段且种类丰富的流感疫苗系列产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900030058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","LU1064130708.USD","BK0188","LU2580892789.USD","BK0046","BK0239","BK0077","LU1064131003.USD","159646","300122","BK0196","LU2148510915.USD","LU1328615791.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766610929801,"stockEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0571},{"period":"3month","weight":-0.0894},{"period":"6month","weight":-0.0139},{"period":"1year","weight":-0.3077},{"period":"ytd","weight":-0.2719}],"compareEarnings":[{"period":"1week","weight":0.0183},{"period":"1month","weight":0.0272},{"period":"3month","weight":0.0227},{"period":"6month","weight":0.1509},{"period":"1year","weight":0.1613},{"period":"ytd","weight":0.1758}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"127955人(较上一季度减少1.63%)","perCapita":"11053股","listingDate":"2010-09-28","address":"重庆市江北区庆云路1号50层","registeredCapital":"239378万元","survey":" 重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是预防流脑疫苗、宫颈癌疫苗、肺炎疫苗、流感疫苗、轮状病疫苗。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}